2025 · Zhang — RNA-Seq Reveals the Mechanism of Synergistic Hydrogen-Chemotherapy Based on Active Magnesium Micromotors for Inhibiting Glioblastoma Recurrence by Modulating Tumor Microenvironment.
Super-Abstract
Glioblastoma (GBM) almost always returns after surgery — and a new approach using self-propelled magnesium micromotors that generate hydrogen gas locally and simultaneously deliver chemotherapy drug doxorubicin may significantly inhibit this recurrence. In a murine post-surgical GBM model, the combined hydrogen-chemotherapy approach suppressed tumour recurrence and — through RNA-seq analysis — was shown to convert immunologically „cold“ tumours into „hot“ ones, activating the immune system against the cancer. This is an animal study; no human data are available. (Small, 2025.)
Commentary
Glioblastoma has one of the worst prognoses in oncology, and postoperative recurrence is the central clinical problem. This paper proposes a creative solution: magnesium micromotors that, upon contact with water in the surgical cavity, react to generate H₂ gas (which propels the micromotors mechanically and simultaneously acts as an antioxidant/anti-neuroinflammatory agent) while releasing doxorubicin (DOX) chemotherapy. The H₂ bubbles create local fluid vortices that enhance DOX penetration into remaining tumour cells. A temperature-sensitive hydrogel serves as the delivery vehicle for local administration. The RNA-seq data provide mechanistic insight into immune microenvironment remodelling — the „cold to hot tumour“ conversion is an immunologically meaningful finding. However, all data are from murine GBM models, which are notoriously poor models for human glioblastoma given differences in immune system composition and tumour biology. The delivery route (intra-cavity administration post-surgery) is plausible clinically but requires safety validation.
Key quotes
- „The produced H2 by the Mg-water reaction not only propels the motion of motors but also functions as an antioxidant to effectively alleviate the neuroinflammation caused by GBM resection.“ — H₂ serves two simultaneous roles: mechanical propellant for drug delivery and anti-inflammatory agent
- „The H2 bubbles create a pronounced vortex flow in situ, greatly enhancing the DOX penetration and the sensitivity of GBM cells to DOX.“ — physical mechanism: H₂ bubble-driven fluid vortex improves chemotherapy penetration
- „RNA-Seq technology further elucidates the role of the strategy in modulating the tumor immune microenvironment via converting cold tumors into hot tumors.“ — RNA-seq confirms immune microenvironment remodelling — from immunologically silent to active
Our assessment
An innovative and mechanistically well-characterized preclinical study addressing the clinically urgent problem of GBM recurrence. The dual-function H₂ concept (propulsion + anti-neuroinflammation) is novel, and the RNA-seq immune profiling adds scientific depth. Decisive limitation: this is an animal study — results cannot be directly transferred to human GBM patients. Murine GBM models differ substantially from human tumours in immune biology, and the surgical delivery scenario requires dedicated safety studies. DOX itself is not standard first-line post-operative GBM therapy (temozolomide is), raising questions about clinical fit. A promising mechanistic foundation, not a clinical finding.
Study design
- Type: animal study (preclinical) · Model: in-situ murine GBM recurrence model (post-subtotal resection) · H₂ delivery: magnesium micromotors (Mg-Motor-DOX) in temperature-sensitive hydrogel — intra-cavity administration; H₂ from Mg-water reaction
- Co-agent: doxorubicin (DOX) released from motors; H₂ bubble vortex enhances DOX penetration
- Result: significant inhibition of GBM recurrence; RNA-seq confirms „cold-to-hot“ tumour immune microenvironment conversion; H₂ reduced post-resection neuroinflammation
Abstract
Postoperative recurrence of glioblastoma (GBM) is a key contributing factor to the unfavorable prognosis of patients. Chemotherapy has been extensively employed as a postoperative treatment for GBM; however, the produced drug resistance significantly undermines the chemotherapeutic efficacy. Herein, a multifunctional system based on magnesium micromotor (Mg-Motor-DOX) is designed and fabricated that can generate hydrogen gas in situ and actively deliver the chemotherapeutic drug doxorubicin (DOX). Utilizing a temperature-sensitive hydrogel, Mg-Motor-DOX is administrated in situ to the residual cavity of the tumor after subtotal GBM resection. The produced H2 by the Mg-water reaction not only propels the motion of motors but also functions as an antioxidant to effectively alleviate the neuroinflammation caused by GBM resection. The H2 bubbles create a pronounced vortex flow in situ, greatly enhancing the DOX penetration and the sensitivity of GBM cells to DOX. Therefore, synergistic hydrogen-chemotherapy significantly inhibits the recurrence of the in situ GBM model. RNA-Seq technology further elucidates the role of the strategy in modulating the tumor immune microenvironment via converting cold tumors into hot tumors, thereby establishing a theoretical foundation for the clinical implementation of synergistic hydrogen-chemotherapy.
Source & links
Screenshot of the PubMed page
This page mirrors the published abstract (© the authors / publisher) for reference and citation. The canonical source is the PubMed record linked above. This is not medical advice.